The next stage of the academic-industrial partnership aims to expand beyond cancer vulnerabilities to investigate cancer resistance, surface targets, and high-dimensional readouts.
Ó³»´«Ã½ researchers Matthew Meyerson and Heidi Greulich describe how they and Bayer scientists developed the first FDA-approved cancer drug to come from a Ó³»´«Ã½ scientific discovery.
Test of circulating tumor cells offers less invasive option for multiple myeloma surveillance, staging, and biological study compared to bone marrow biopsies